In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 131 to 140 of 342

TitleTypeExpected publication date
Ianalumab for treating active Sjogren's syndrome [ID6634]Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]Technology appraisal guidanceTBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596Technology appraisal guidanceTBC
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]Technology appraisal guidanceTBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over ID6579Technology appraisal guidanceTBC
ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)Technology appraisal guidance
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidance
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Technology appraisal guidance
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All